SCHEMBL9709138

SCHEMBL9709138

CCCSCCCCCCCCCCCCCC(=O)OC(=O)CCCCCCCCSC

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.42
DGKA P23743 1/20 0.39
MAPT P10636 3/20 0.38
CES2 O00748 3/20 0.38
GMNN O75496 1/20 0.38
TP53 P04637 1/20 0.38
POLB P06746 1/20 0.38
THRB P10828 1/20 0.38
CYP2C9 P11712 1/20 0.38
BLM P54132 1/20 0.38
HSD17B10 Q99714 1/20 0.38
LMNA P02545 2/20 0.37
PAM P19021 2/20 0.36
MAPK1 P28482 1/20 0.35
ESR1 P03372 1/20 0.35
ESR2 Q92731 1/20 0.35
FAAH O00519 4/20 0.34
CES1 P23141 4/20 0.34
PLA2G6 O60733 1/20 0.34
TSHR P16473 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9709135 0.82 GPR84 (0.52) ALDH1A1MAPTGMNNTP53POLB
SCHEMBL7793662 0.80 DGKA (0.52) ALDH1A1DGKAMAPTCES2HSD17B10
SCHEMBL19071558 0.80 TSHR (0.52) ALDH1A1DGKAMAPTCES2GMNN
Iodide SCHEMBL6069090 0.79 DGKA (0.50) ALDH1A1DGKAMAPTCES2LMNA
SCHEMBL26650862 0.79 TSHR (0.50) ALDH1A1DGKAMAPTCES2GMNN
SCHEMBL849161 0.79 DGKA (0.50) ALDH1A1DGKAMAPTHSD17B10LMNA
SCHEMBL29435917 0.78 DGKA (0.53) ALDH1A1DGKAMAPTCES2HSD17B10
SCHEMBL4446360 0.78 DGKA (0.53) ALDH1A1DGKAMAPTCES2HSD17B10
SCHEMBL2898744 0.78 DGKA (0.53) ALDH1A1DGKAMAPTCES2HSD17B10
SCHEMBL3918186 0.78 DGKA (0.53) ALDH1A1DGKAMAPTCES2HSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-1992018132-A1 PHARMACEUTICAL COMBINATION FOR THE TREATMENT OF BENIGN PROSTATIC HYPERPLASIA COMTAINING A 5 ALPHA-REDUCTASE INHIBITOR MERCK & CO., INC. (US) 1992-10-29 WO disclosed
WO-1992016233-A1 PHARMACEUTICAL COMBINATION FOR THE TREATMENT OF PROSTATIC CANCER CONTAINING A 5 ALPHA REDUCTASE INHIBITOR AND AN ANTIANDROGEN MERCK & CO., INC. (US) 1992-10-01 WO disclosed